Compare Stocks: GHRS, LNTH, LQDA, and AMRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$17.25 +1.2%	$17.77	$9.49 ▼ $19.26	$5.44B	1.24	1.66 million shs	1.47 million shs
GHRS GH Research	$27.56 -0.8%	$28.18	$11.83 ▼ $31.44	$1.91B	1.27	228,326 shs	336,794 shs
LNTH Lantheus	$100.70 +0.3%	$102.57	$49.67 ▼ $111.86	$6.56B	-0.03	1.18 million shs	704,247 shs
LQDA Liquidia	$69.12 +2.1%	$77.93	$21.15 ▼ $93.61	$6.06B	0.53	1.49 million shs	997,251 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	+1.17%	-4.49%	-3.52%	+5.57%	+74.42%
GHRS GH Research	-0.83%	-1.82%	-6.67%	+33.68%	+105.37%
LNTH Lantheus	+0.26%	-0.11%	-0.28%	-3.47%	+82.86%
LQDA Liquidia	+2.13%	-0.80%	-24.07%	-3.50%	+148.63%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$17.25 +1.2%	$17.77	$9.49 ▼ $19.26	$5.44B	1.24	1.66 million shs	1.47 million shs
GHRS GH Research	$27.56 -0.8%	$28.18	$11.83 ▼ $31.44	$1.91B	1.27	228,326 shs	336,794 shs
LNTH Lantheus	$100.70 +0.3%	$102.57	$49.67 ▼ $111.86	$6.56B	-0.03	1.18 million shs	704,247 shs
LQDA Liquidia	$69.12 +2.1%	$77.93	$21.15 ▼ $93.61	$6.06B	0.53	1.49 million shs	997,251 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	+1.17%	-4.49%	-3.52%	+5.57%	+74.42%
GHRS GH Research	-0.83%	-1.82%	-6.67%	+33.68%	+105.37%
LNTH Lantheus	+0.26%	-0.11%	-0.28%	-3.47%	+82.86%
LQDA Liquidia	+2.13%	-0.80%	-24.07%	-3.50%	+148.63%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRX Amneal Pharmaceuticals	2.89	Moderate Buy	$19.57	13.46% Upside
GHRS GH Research	2.75	Moderate Buy	$45.00	63.28% Upside
LNTH Lantheus	2.29	Hold	$108.11	7.36% Upside
LQDA Liquidia	2.45	Hold	$98.08	41.90% Upside

Current Analyst Ratings Breakdown

Latest GHRS, LNTH, LQDA, and AMRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	AMRX Amneal Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$23.00
9/7/2026	AMRX Amneal Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/27/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/26/2026	AMRX Amneal Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/26/2026	AMRX Amneal Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$22.00
8/17/2026	LNTH Lantheus	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/13/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
8/13/2026	LQDA Liquidia	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$106.00
8/13/2026	LQDA Liquidia	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$62.00 ➝ $108.00
8/13/2026	GHRS GH Research	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/13/2026	LQDA Liquidia	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRX Amneal Pharmaceuticals	$3.02B	1.82	$1.58 per share	10.92	($0.23) per share	-75.00
GHRS GH Research	N/A	N/A	N/A	N/A	$4.51 per share	N/A
LNTH Lantheus	$1.54B	4.26	$6.40 per share	15.73	$16.43 per share	6.13
LQDA Liquidia	$158.32M	39.08	N/A	N/A	$0.51 per share	135.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRX Amneal Pharmaceuticals	$72.06M	$0.49	35.20	15.97	N/A	5.05%	-584.46%	7.78%	N/A
GHRS GH Research	-$48.26M	-$1.00	N/A	N/A	N/A	N/A	-20.86%	-20.12%	11/5/2026 (Estimated)
LNTH Lantheus	$233.56M	$4.14	24.32	18.44	N/A	17.69%	28.10%	14.35%	11/5/2026 (Estimated)
LQDA Liquidia	-$68.92M	$1.37	50.45	15.78	N/A	30.74%	149.65%	36.30%	11/2/2026 (Estimated)

Latest GHRS, LNTH, LQDA, and AMRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	LQDA Liquidia	$0.7580	$0.74	-$0.0180	$0.74	$168.48 million	$171.68 million
8/6/2026	Q2 2026	GHRS GH Research	-$0.2860	-$0.23	+$0.0560	-$0.23	N/A	N/A
8/6/2026	Q2 2026	LNTH Lantheus	$1.30	$1.55	+$0.25	$1.11	$363.23 million	$388.18 million
7/30/2026	Q2 2026	AMRX Amneal Pharmaceuticals	$0.24	$0.30	+$0.06	$0.18	N/A	$796.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRX Amneal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRX Amneal Pharmaceuticals	77.65	2.20	1.44
GHRS GH Research	N/A	28.70	28.70
LNTH Lantheus	0.43	3.06	2.89
LQDA Liquidia	0.63	2.31	2.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMRX Amneal Pharmaceuticals	31.82%
GHRS GH Research	56.90%
LNTH Lantheus	99.06%
LQDA Liquidia	64.54%

Insider Ownership

Company	Insider Ownership
AMRX Amneal Pharmaceuticals	17.30%
GHRS GH Research	41.60%
LNTH Lantheus	1.70%
LQDA Liquidia	25.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRX Amneal Pharmaceuticals	8,500	319.35 million	264.11 million	Optionable
GHRS GH Research	10	68.61 million	40.07 million	Optionable
LNTH Lantheus	1,193	65.27 million	64.16 million	Optionable
LQDA Liquidia	50	89.51 million	66.60 million	Optionable

GHRS, LNTH, LQDA, and AMRX Headlines

Recent News About These Companies

Wellington Management Group LLP Sells 22,925 Shares of Liquidia Corporation $LQDA

September 8 at 4:48 AM | marketbeat.com

Liquidia Corporation Receives FDA Fast Track Designation For YUTREPIA For Raynaud's Phenomenon Associated With Systemic Sclerosis

September 4, 2026 | marketscreener.comM

Liquidia Gains FDA Fast Track For YUTREPIA In Raynaud's Linked To Systemic Sclerosis

September 3, 2026 | rttnews.com

Liquidia Says US FDA Grants Fast Track Designation to Yutrepia in Systemic Sclerosis

September 3, 2026 | finance.yahoo.com

Liquidia Corporation’s (LQDA) Yutrepia Launch Continues to Outpace the Expectations

September 3, 2026 | insidermonkey.com

Liquidia Corporation’s (LQDA) Yutrepia Launch Continues to Outpace the Expectations

September 3, 2026 | finance.yahoo.com

Liquidia Gains FDA Fast Track for YUTREPIA in Raynaud’s

September 3, 2026 | tipranks.com

Liquidia’s YUTREPIA Receives FDA Fast Track Designation for Systemic Sclerosis-Associated Raynaud’s Phenomenon

September 3, 2026 | quiverquant.comQ

FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis

September 3, 2026 | globenewswire.com

Liquidia Corporation $LQDA Shares Sold by Pale Fire Capital SE

September 3, 2026 | marketbeat.com

Liquidia Corporation (NASDAQ:LQDA) Receives Average Rating of "Hold" from Analysts

September 3, 2026 | americanbankingnews.com

Liquidia Corporation (NASDAQ:LQDA) Given Consensus Recommendation of "Hold" by Analysts

September 3, 2026 | marketbeat.com

Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress

September 2, 2026 | globenewswire.com

Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference

September 1, 2026 | globenewswire.com

Are Options Traders Betting on a Big Move in Jack in the Box Stock?

August 31, 2026 | msn.com

Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

August 31, 2026 | zacks.com

Is the Options Market Predicting a Spike in Liquidia Stock?

August 31, 2026 | zacks.com

Bank of New York Mellon Corp Makes New Investment in Liquidia Corporation $LQDA

August 30, 2026 | marketbeat.com

Liquidia Corp (LQDA) Stock Down 3.1% -- Now Undervalued? GF Score: 70/100

August 28, 2026 | gurufocus.com

Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?

August 27, 2026 | zacks.com

Liquidia Corporation $LQDA Shares Bought by Seven Fleet Capital Management LP

August 27, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS, LNTH, LQDA, and AMRX Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

$17.25 +0.20 (+1.17%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$17.22 -0.04 (-0.20%)

As of 07:25 AM Eastern

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

GH Research NASDAQ:GHRS

$27.56 -0.23 (-0.83%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$28.83 +1.27 (+4.62%)

As of 07:03 AM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Lantheus NASDAQ:LNTH

$100.70 +0.26 (+0.26%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$100.29 -0.41 (-0.40%)

As of 07:20 AM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Liquidia NASDAQ:LQDA

$69.12 +1.44 (+2.13%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$69.16 +0.04 (+0.05%)

As of 07:03 AM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GHRS, LNTH, LQDA, and AMRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GHRS, LNTH, LQDA, and AMRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GHRS, LNTH, LQDA, and AMRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS, LNTH, LQDA, and AMRX Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

GH Research NASDAQ:GHRS

Lantheus NASDAQ:LNTH

Liquidia NASDAQ:LQDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GHRS, LNTH, LQDA, and AMRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GHRS, LNTH, LQDA, and AMRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GHRS, LNTH, LQDA, and AMRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS, LNTH, LQDA, and AMRX Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

GH Research NASDAQ:GHRS

Lantheus NASDAQ:LNTH

Liquidia NASDAQ:LQDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools